

## **Product** Data Sheet

## Lumretuzumab

**Cat. No.:** HY-P99304

**CAS No.:** 1448327-63-6

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## **BIOLOGICAL ACTIVITY**

Description	lem:lem:lem:lem:lem:lem:lem:lem:lem:lem:
IC <sub>50</sub> & Target	HER3

## **REFERENCES**

[1]. Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors • Scr

Screening Libraries

Proteins